Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

Source:http://linkedlifedata.com/resource/pubmed/id/2213100

Download in:

View as

General Info

PMID
2213100